// Research pages, Clinical Trials, Publications & Presentations, Global Collaboration.

// -------- Clinical Trials -------------------------------------------------

function ClinicalTrialsPage({ navigate }) {
  return (
    <div data-screen-label="Clinical Trials">
 <PageHero
        eyebrow="Research"
        title="Clinical trials, SCN2A and DEE."
        body="Clinical trials are how new treatments get tested, approved, and eventually made available to families. For a condition as rare as SCN2A, trial participation by eligible families is one of the most direct ways to accelerate the path to approved therapies."
        ledger={["TABLE LAST REVIEWED · MARCH 2026", "REVIEWED QUARTERLY", "ALWAYS DISCUSS WITH YOUR NEUROLOGIST FIRST"]}
        navigate={navigate} />
      
 <Breadcrumbs items={[{ label: 'Driving Change', to: 'change' }, { label: 'Clinical trials' }]} navigate={navigate} />

 <section style={{ background: '#fff', padding: '56px 0 32px' }}>
 <div className="container">
 <SafetyCallout label="GoF / LoF, why this matters for trial eligibility">
 <p style={{ margin: '0 0 10px' }}>For SCN2A families, whether your child has a <strong>gain-of-function (GoF)</strong> or <strong>loss-of-function (LoF)</strong> variant is critical to trial eligibility, and to medication safety.</p>
 <ul style={{ margin: '8px 0 12px', paddingLeft: 20 }}>
 <li><strong>GoF variants</strong>, channel overactive. Sodium channel blockers and ASOs targeting SCN2A expression are appropriate. Same treatments can be harmful in LoF.</li>
 <li><strong>LoF variants</strong>, channel underactive. Treatments that increase or compensate for reduced function are the focus. Sodium channel blockers are contraindicated.</li>
 </ul>
 <p style={{ margin: 0 }}>If you are unsure of your child's variant type, speak with your neurologist or genetic counsellor before enquiring about any trial. <a href="#genetics" onClick={(e) => {e.preventDefault();navigate('genetics');}} className="link">Read our genetics guide</a></p>
 </SafetyCallout>
 </div>
 </section>

 {/* SCN2A-specific trials */}
 <section style={{ background: '#fff', padding: '40px 0 64px' }}>
 <div className="container">
 <div style={{ marginBottom: 24, maxWidth: 760 }}>
 <div className="eyebrow">SCN2A-specific trials</div>
 <h2 className="h2-mobile" style={{ fontSize: 'clamp(28px, 3.4vw, 40px)', fontWeight: 700, color: '#0D1B2A', margin: '14px 0 0', lineHeight: 1.15 }}>The current SCN2A trial landscape.</h2>
 </div>

 {/* Elsunersen */}
 <article style={{ border: '1px solid #D5CFBF', background: '#fff', marginBottom: 18 }}>
 <header style={{ padding: '22px 28px', background: '#1E3A6E', color: '#fff', display: 'grid', gridTemplateColumns: '1fr auto', alignItems: 'center', gap: 16 }} className="stack-mobile-2">
 <div>
 <div className="ledger-mono" style={{ fontSize: 11, color: '#E8E3DA', letterSpacing: '0.1em' }}>PHASE 3 · REGISTRATIONAL</div>
 <h3 style={{ fontSize: 24, fontWeight: 700, color: '#fff', margin: '6px 0 0', letterSpacing: '-0.005em' }}>Elsunersen (PRAX-222), EMBRAVE / EMBRAVE3</h3>
 <div style={{ fontSize: 14, color: 'rgba(255,255,255,0.78)', marginTop: 4 }}>Antisense oligonucleotide · Praxis Precision Medicines</div>
 </div>
 <span className="chip" style={{ background: '#fff', color: '#0D1B2A' }}>GoF only</span>
 </header>
 <div style={{ padding: '24px 28px' }}>
 <table>
 <tbody>
 <tr><th>Sponsor</th><td>Praxis Precision Medicines</td></tr>
 <tr><th>Eligible variants</th><td><strong>Gain of function (GoF) only</strong></td></tr>
 <tr><th>Conditions</th><td>Early-onset SCN2A-DEE</td></tr>
 <tr><th>Status</th><td>Actively enrolling, EMBRAVE3 converted to single-arm, open-label design (December 2025); all participants receive active treatment</td></tr>
 <tr><th>Where</th><td>International multi-site, see embravestudy.com for current sites</td></tr>
 <tr><th>Topline results expected</th><td>H1 2026 (EMBRAVE Part A); ongoing enrolment for EMBRAVE3</td></tr>
 </tbody>
 </table>
 <p style={{ fontSize: 15, lineHeight: 1.65, color: '#0D1B2A', margin: '16px 0 0' }}>
 Elsunersen is an ASO designed to selectively reduce SCN2A gene expression, directly targeting the underlying mechanism of early-onset SCN2A-DEE in patients with GoF variants. Administered by lumbar puncture (intrathecal injection). The EMBRAVE Phase 1/2 study reported a <strong>44% median seizure reduction</strong> following three doses. EMBRAVE3 is the registrational Phase 3 study; the FDA agreed in December 2025 to a simplified, single-arm design with 30 participants, all receiving active treatment.
 </p>
 <div style={{ marginTop: 16, display: 'flex', gap: 12, flexWrap: 'wrap' }}>
 <Button size="sm" variant="outline" as="a" href="https://www.embravestudy.com">EMBRAVE study site</Button>
 <Button size="sm" variant="ghost" as="a" href="https://www.praxismedicines.com">Praxis pipeline</Button>
 </div>
 </div>
 </article>

 {/* Relutrigine */}
 <article style={{ border: '1px solid #D5CFBF', background: '#fff' }}>
 <header style={{ padding: '22px 28px', background: '#1E3A6E', color: '#fff', display: 'grid', gridTemplateColumns: '1fr auto', alignItems: 'center', gap: 16 }} className="stack-mobile-2">
 <div>
 <div className="ledger-mono" style={{ fontSize: 11, color: '#E8E3DA', letterSpacing: '0.1em' }}>PHASE 2/3 · NDA SUBMITTED EARLY 2026</div>
 <h3 style={{ fontSize: 24, fontWeight: 700, color: '#fff', margin: '6px 0 0', letterSpacing: '-0.005em' }}>Relutrigine (PRAX-562), EMBOLD</h3>
 <div style={{ fontSize: 14, color: 'rgba(255,255,255,0.78)', marginTop: 4 }}>Persistent sodium current inhibitor · Praxis Precision Medicines</div>
 </div>
 <span className="chip" style={{ background: '#fff', color: '#8E3B5E' }}>LoF · SCN2A + SCN8A</span>
 </header>
 <div style={{ padding: '24px 28px' }}>
 <table>
 <tbody>
 <tr><th>Eligible variants</th><td><strong>Loss of function (LoF)</strong>, SCN2A-DEE and SCN8A-DEE</td></tr>
 <tr><th>Conditions</th><td>SCN2A-DEE (LoF), SCN8A-DEE</td></tr>
 <tr><th>Status</th><td>Trial stopped early for efficacy; NDA submitted to FDA in early 2026. Not actively enrolling new participants in the original trial, open-label extension ongoing.</td></tr>
 <tr><th>FDA designations</th><td>Breakthrough Therapy · Orphan Drug · Rare Pediatric Disease</td></tr>
 </tbody>
 </table>
 <p style={{ fontSize: 15, lineHeight: 1.65, color: '#0D1B2A', margin: '16px 0 0' }}>
 First-in-class small molecule that preferentially inhibits persistent sodium current, a key driver of seizures in SCN2A-DEE (LoF) and SCN8A-DEE. The EMBOLD Phase 2/3 study was stopped early after a Data Monitoring Committee recommendation based on strong efficacy, a <strong>53% placebo-adjusted seizure reduction</strong> alongside improvements in behaviour and function. An NDA has been submitted to the FDA. <strong>If approved, this would be the first drug specifically indicated for SCN2A-DEE.</strong>
 </p>
 </div>
 </article>
 </div>
 </section>

 {/* Broader DEE trials */}
 <section style={{ background: '#F7F4F0', padding: '72px 0' }}>
 <div className="container">
 <div style={{ marginBottom: 24, maxWidth: 760 }}>
 <div className="eyebrow">Broader DEE trials</div>
 <h2 className="h2-mobile" style={{ fontSize: 'clamp(28px, 3.4vw, 40px)', fontWeight: 700, color: '#0D1B2A', margin: '14px 0 0', lineHeight: 1.15 }}>May be open to SCN2A families.</h2>
 <p style={{ fontSize: 15, color: '#6B6659', margin: '14px 0 0', maxWidth: 620, lineHeight: 1.65 }}>Not SCN2A-specific but open to participants with a range of DEE diagnoses. Eligibility varies, always confirm with the trial team and your neurologist.</p>
 </div>
 <div style={{ display: 'grid', gridTemplateColumns: 'repeat(2, 1fr)', gap: 18 }} className="stack-mobile">
 <article style={{ background: '#fff', border: '1px solid #D5CFBF', padding: '24px 28px' }}>
 <div className="ledger-mono" style={{ fontSize: 11, color: '#0D1B2A', letterSpacing: '0.1em' }}>PHASE 2/3 · RECRUITING</div>
 <h3 style={{ fontSize: 20, fontWeight: 700, color: '#0D1B2A', margin: '8px 0 4px' }}>LP352, DEEp OCEAN Study</h3>
 <div style={{ fontSize: 13, color: '#6B6659' }}>5-HT2c receptor superagonist · Longboard Pharmaceuticals</div>
 <p style={{ fontSize: 14.5, lineHeight: 1.65, color: '#0D1B2A', margin: '14px 0' }}>The only 5-HT2c receptor superagonist in development dose-optimised for refractory epilepsy populations. Double-blind, placebo-controlled, multi-centre trial investigating efficacy in children and adults with DEE, including Dravet, Lennox-Gastaut, and other DEEs. SCN2A families with a DEE diagnosis may be eligible.</p>
 <Button size="sm" variant="outline" as="a" href="https://clinicaltrials.gov/study/NCT06719141">View on ClinicalTrials.gov</Button>
 </article>
 <article style={{ background: '#fff', border: '1px solid #D5CFBF', padding: '24px 28px' }}>
 <div className="ledger-mono" style={{ fontSize: 11, color: '#6B6659', letterSpacing: '0.1em' }}>OPEN-LABEL EXTENSION · NOT RECRUITING NEW</div>
 <h3 style={{ fontSize: 20, fontWeight: 700, color: '#0D1B2A', margin: '8px 0 4px' }}>Soticlestat (TAK-935)</h3>
 <div style={{ fontSize: 13, color: '#6B6659' }}>CH24H inhibitor · Takeda Pharmaceuticals</div>
 <p style={{ fontSize: 14.5, lineHeight: 1.65, color: '#0D1B2A', margin: '14px 0' }}>Inhibits cholesterol 24-hydroxylase, involved in regulating neuronal excitability. Phase 3 trials showed mixed results on primary endpoints for Dravet and Lennox-Gastaut syndromes. The open-label extension is ongoing for prior participants. Not currently recruiting new participants, listed here for information only.</p>
 </article>
 </div>
 </div>
 </section>

 {/* Pipeline */}
 <section style={{ background: '#fff', padding: '72px 0' }}>
 <div className="container">
 <div style={{ marginBottom: 24, maxWidth: 760 }}>
 <div className="eyebrow">Pipeline</div>
 <h2 className="h2-mobile" style={{ fontSize: 'clamp(28px, 3.4vw, 40px)', fontWeight: 700, color: '#0D1B2A', margin: '14px 0 0', lineHeight: 1.15 }}>Not yet in clinical trials.</h2>
 <p style={{ fontSize: 15, color: '#6B6659', margin: '14px 0 0', maxWidth: 620, lineHeight: 1.65 }}>Preclinical or early-stage approaches, listed so families can follow the pipeline and understand what may be coming.</p>
 </div>
 <div style={{ display: 'grid', gridTemplateColumns: 'repeat(3, 1fr)', gap: 18 }} className="stack-mobile">
 <article style={{ border: '1px solid #D5CFBF', padding: '22px 24px', background: '#fff' }}>
 <div className="ledger-mono" style={{ fontSize: 11, color: '#0D1B2A', letterSpacing: '0.1em' }}>GENE THERAPY · PRECLINICAL</div>
 <h3 style={{ fontSize: 18, fontWeight: 700, color: '#0D1B2A', margin: '8px 0 4px' }}>RT-102, Regel Therapeutics</h3>
 <p style={{ fontSize: 14, lineHeight: 1.6, color: '#6B6659', margin: '8px 0 12px' }}>Gene therapy for SCN2A haploinsufficiency (LoF). Uses a deactivated CRISPR-Cas system (dCas) to epigenetically upregulate SCN2A expression without editing or damaging the DNA. The leading gene therapy approach for LoF variants.</p>
 <a href="https://regeltherapeutics.com/pipeline/" target="_blank" rel="noopener" className="link" style={{ fontSize: 13 }}>Pipeline</a>
 </article>
 <article style={{ border: '1px solid #D5CFBF', padding: '22px 24px', background: '#fff' }}>
 <div className="ledger-mono" style={{ fontSize: 11, color: '#0D1B2A', letterSpacing: '0.1em' }}>INDIVIDUALISED ASO · ACCESS PROGRAM</div>
 <h3 style={{ fontSize: 18, fontWeight: 700, color: '#0D1B2A', margin: '8px 0 4px' }}>n-Lorem Foundation</h3>
 <p style={{ fontSize: 14, lineHeight: 1.6, color: '#6B6659', margin: '8px 0 12px' }}>Develops bespoke antisense oligonucleotide therapies for individual patients with ultra-rare genetic conditions. Two SCN2A-DEE participants have been treated under compassionate/individual access. Not a clinical trial.</p>
 <a href="https://nlorem.org" target="_blank" rel="noopener" className="link" style={{ fontSize: 13 }}>n-Lorem Foundation</a>
 </article>
 <article style={{ border: '1px solid #D5CFBF', padding: '22px 24px', background: '#fff' }}>
 <div className="ledger-mono" style={{ fontSize: 11, color: '#0D1B2A', letterSpacing: '0.1em' }}>CRISPRa · RESEARCH STAGE</div>
 <h3 style={{ fontSize: 18, fontWeight: 700, color: '#0D1B2A', margin: '8px 0 4px' }}>CRISPRa gene activation</h3>
 <p style={{ fontSize: 14, lineHeight: 1.6, color: '#6B6659', margin: '8px 0' }}>Researchers are investigating CRISPR-activation approaches to restore SCN2A expression in LoF patients. Early-stage laboratory research, no clinical programme announced.</p>
 </article>
 </div>
 </div>
 </section>

 <ProseSection eyebrow="Finding out more" title="Where to look next." background="#F7F4F0">
 <p><strong>Talk to your neurologist first.</strong> Trial eligibility is complex, your child's treating team needs to assess whether a trial is appropriate based on variant type, age, seizure history, current medications, and other clinical factors.</p>
 <ResourceList title="Useful trial-finding resources" items={[
        { label: 'ClinicalTrials.gov', body: 'Search "SCN2A" or "DEE" for all registered trials', url: 'https://clinicaltrials.gov' },
        { label: 'SCN2A Clinical Trials', body: 'SCN2A-specific trial information resource', url: 'https://www.scn2aclinicaltrials.com' }]
        } />
 <p style={{ marginTop: 18 }}><strong>SCN2A Australia does not enrol families into trials directly.</strong> We can help you understand the landscape and connect you with the right clinical contacts.</p>
 </ProseSection>

 <CTABlock
        eyebrow="Stay connected"
        title="Families on the registry may be contacted about relevant trial opportunities as they arise."
        body="It is one of the most practical things you can do now to stay connected to the research pipeline."
        ctaLabel="Contact us with trial questions"
        onCta={() => navigate('contact')}
        secondaryLabel="Genetics & diagnosis"
        onSecondary={() => navigate('genetics')} />
      

 <RelatedPages
        items={[
        { label: 'Genetics & diagnosis', to: 'genetics' },
        { label: 'SCN2A-related disorders', to: 'scn2a-disorders' },
        { label: 'Our Impact, research network', to: 'impact' },
        { label: 'Publications & presentations', to: 'publications' }]
        }
        navigate={navigate} />
      
 </div>);

}

// -------- Publications & Presentations ------------------------------------

function PublicationsPage({ navigate }) {
  const pubs = [
  { year: '2025', featured: true, authors: 'Pierce, K., Murphy, J. B., Robertson, E. G., Khan, J. R., Bullock, S., O\u2019Loughlin, C. B., Loden, M., McIntosh, R., Beavis, E., Roberts, N., Palmer, E. E., & Lingam, R. (2025).', title: '\u201CJust realising that I wasn\u2019t alone\u2026 was profound\u201D: A mixed-methods evaluation of a pilot peer-to-peer wellbeing program for carers of children with rare epilepsies.', source: 'Orphanet Journal of Rare Diseases, 20.', link: 'https://doi.org/10.1186/s13023-025-04036-0', note: 'Kris Pierce, first author' },
  { year: '2025', authors: 'Ewans, L. J., Pierce, K., Farley, E., Bowden, R., Shalhoub, C., & Palmer, E. E. (2025).', title: 'I\u2019ve never heard of this! An approach to child and family-centred care for children and young people with rare diseases.', source: 'Journal of Paediatrics and Child Health.', link: 'https://doi.org/10.1111/jpc.70267', note: 'Advance online publication' },
  { year: '2025', authors: 'Fisher, L., Stirling, M., Jones, R., Pierce, K., Lingam, R., Marshall, G. M., Hiscock, H., & Dalziel, K. (2025).', title: 'Establishing research priorities for children living with chronic health conditions: A value-weighting study by Australian caregivers.', source: 'Journal of Paediatrics and Child Health, 61(10), 1646\u20131654.', link: 'https://doi.org/10.1111/jpc.70128' },
  { year: '2025', authors: 'Pierce, K., Single, A., Funk, M., & Van Gorp, K. (2025).', title: 'OP07 Shared learning: An alternative model for patient capacity development to participate in health technology assessment.', source: 'International Journal of Technology Assessment in Health Care, 41(S1), S4.', link: 'https://doi.org/10.1017/S0266462325100664', note: 'Conference abstract \u00b7 Kris Pierce, first author' },
  { year: '2025', status: 'Accepted', authors: 'Kelada, L., Best, S., Pierce, K., Allen, M., Cobb, J., Berens, K., Goranitis, I., Palmer, E. E., Scheffer, I. E., & Howell, K. B. (2025).', title: 'Fulfilling the needs of caregivers in delivering health services to children with developmental and epileptic encephalopathies.', source: 'European Journal of Paediatric Neurology.' },
  { year: '2025', status: 'In press', authors: 'Truong, L., et al. (2025).', title: 'Patient-centric epilepsy clinical trial model for improved health outcomes using cannabidiol (PACIFIC study): A methodology for developing patient-centred clinical trials in rare epilepsy syndromes.' },
  { year: '2025', status: 'Preprint', authors: 'Rush, A., Gomez, M., Pierce, K., De Abreu Lourenco, R., Mason, K., Howard, K., Lynch, G., Walker, P., Viney, R., & Watson, J. (2025).', title: 'Patient, consumer and societal values, perceptions and preferences on high-cost gene therapies.', source: 'Research Square.', link: 'https://doi.org/10.21203/rs.3.rs-7872591/v1', note: 'Preprint, not yet peer-reviewed' },
  { year: '2025', status: 'Report', authors: 'Levine, D. S., Beek, G., Bichell, T. J., Boice, N., Brown, C., Cobb, M., Erler, W., Flesch, M., MacDonnell, K., Martinez-Rubio, C., McBride, A., Pierce, K., Sanandaji, P., Scipione, F., Smith, R., & Son Rigby, C. (2025).', title: 'Early and often: Reimagining patient community engagement to improve clinical trials feasibility.', source: 'Global Genes.', link: 'https://globalgenes.org/wp-content/uploads/feasbility-report-2025.pdf' },
  { year: '2024', status: 'Conference presentation', authors: 'Kelada, L., Best, S., Pierce, K., Allen, M., Cobb, J., Berens, K., Goranitis, I., Palmer, E. E., Scheffer, I. E., & Howell, K. B. (2024).', title: 'Are health services for patients with severe epilepsy meeting families\u2019 needs? Caregiver priorities for improvement.', source: '38th Annual Conference of the European Health Psychology Society, Cascais, Portugal.', note: 'Oral presentation, 3\u20136 September 2024' },
  { year: '2024', authors: 'Gattrell, W. T., Logullo, P., van Zuuren, E. J., Price, A., Hughes, E. L., et al. (2024).', title: 'ACCORD (ACcurate COnsensus Reporting Document): A reporting guideline for consensus methods in biomedicine developed via a modified Delphi.', source: 'PLOS Medicine, 21(1), e1004326.', link: 'https://doi.org/10.1371/journal.pmed.1004326' },
  { year: '2023', authors: 'Robertson, E. G., Roberts, N. J., Le Marne, F., Beavis, E., Macintosh, R., Kelada, L., Best, S., Goranitis, I., Pierce, K., Gill, D., Sachdev, R., Bye, A., & Palmer, E. E. (2023).', title: '\u201CSomewhere to turn to with my questions\u201D: A pre-post pilot of an information linker service for caregivers who have a child with a developmental and epileptic encephalopathy.', source: 'European Journal of Paediatric Neurology, 47, 94\u2013104.', link: 'https://doi.org/10.1016/j.ejpn.2023.09.010' },
  { year: '2023', authors: 'Robertson, E. G., Kelada, L., Best, S., Goranitis, I., Pierce, K., CoGENeS Group, Bye, A., & Palmer, E. E. (2023).', title: 'Quality of life in caregivers of a child with a developmental and epileptic encephalopathy.', source: 'Developmental Medicine & Child Neurology.', link: 'https://doi.org/10.1111/dmcn.15695' },
  { year: '2022', authors: 'Robertson, E. G., Kelada, L., Best, S., Goranitis, I., Grainger, N., Le Marne, F., Pierce, K., Nevin, S. M., Macintosh, R., Beavis, E., Sachdev, R., Bye, A., & Palmer, E. E. (2022).', title: 'Acceptability and feasibility of an online information linker service for caregivers who have a child with genetic epilepsy: A mixed-method pilot study protocol.', source: 'BMJ Open, 12, e063249.', link: 'https://doi.org/10.1136/bmjopen-2022-063249' },
  { year: '2022', authors: 'McLoone, J., Wakefield, C. E., Marshall, G. M., Pierce, K., Jaffe, A., et al. (2022).', title: 'It\u2019s made a really hard situation even more difficult: The impact of COVID-19 on families of children with chronic illness.', source: 'PLOS ONE, 17(9), e0273622.', link: 'https://doi.org/10.1371/journal.pone.0273622' },
  { year: '2021', status: 'Report', authors: 'World Health Organization. (2021).', title: 'How to plan and conduct telehealth consultations with children and adolescents.', source: 'World Health Organization.' }];

  return (
    <div data-screen-label="Publications & Presentations">
 <PageHero
        eyebrow="Research"
        title="Publications & presentations."
        body="SCN2A Australia contributes directly to the evidence base for SCN2A and DEE, through peer-reviewed research, policy submissions, conference presentations, and knowledge translation. Our work bridges lived family experience and rigorous evidence."
        ledger={["15 PEER-REVIEWED PUBLICATIONS", "8 CONFERENCE PRESENTATIONS", "2 INTERNATIONAL POSTERS"]}
        navigate={navigate} />
      
 <Breadcrumbs items={[{ label: 'About', to: 'about' }, { label: 'Publications & presentations' }]} navigate={navigate} />

 <section style={{ background: '#fff', padding: '64px 0' }}>
 <div className="container">
 <div style={{ display: 'grid', gridTemplateColumns: 'repeat(3, 1fr)', borderTop: '1px solid #0D1B2A', borderBottom: '1px solid #0D1B2A' }} className="stack-mobile-2">
 {[
            { fig: '15', l: 'Peer-reviewed publications', n: 'rare disease, HTA, genomics' },
            { fig: '9', l: 'MRFF-funded grants', n: '5 CI · 4 AI' },
            { fig: '10', l: 'Conferences', n: '8 presentations · 2 posters' }].
            map((s, i) =>
            <div key={s.l} style={{
              padding: '32px 28px', borderRight: i < 2 ? '1px solid #D5CFBF' : 'none'
            }}>
 <div style={{ fontSize: 64, fontWeight: 800, color: '#0D1B2A', lineHeight: 0.95, letterSpacing: '-0.03em' }}>{s.fig}</div>
 <div style={{ marginTop: 16, fontSize: 16, fontWeight: 700, color: '#0D1B2A' }}>{s.l}</div>
 <div style={{ marginTop: 4, fontSize: 13, color: '#6B6659' }}>{s.n}</div>
 </div>
            )}
 </div>
 </div>
 </section>

 <ProseSection eyebrow="Peer-reviewed" title="Publications register." background="#F7F4F0">
 <p>Our complete register of peer-reviewed publications, preprints, reports, and conference presentations, listed most recent first. Citations follow APA 7th edition.</p>
 {['2025', '2024', '2023', '2022', '2021'].map((yr) => {
          const items = pubs.filter((p) => p.year === yr);
          if (!items.length) return null;
          return (
            <div key={yr} style={{ marginTop: 28 }}>
 <h4 style={{ display: 'flex', alignItems: 'baseline', gap: 12 }}>
 <span>{yr}</span>
 <span style={{ flex: 1, height: 1, background: '#D5CFBF' }}></span>
 </h4>
 <div style={{ display: 'flex', flexDirection: 'column', gap: 16 }}>
 {items.map((p, i) =>
                <div key={i} style={{ background: '#fff', padding: '20px 22px', borderLeft: '4px solid ' + (p.featured ? '#8E3B5E' : '#0D1B2A') }}>
 {(p.featured || p.status) &&
                  <div className="eyebrow" style={{ color: p.featured ? '#8E3B5E' : '#0D1B2A', marginBottom: 8 }}>
 {p.featured ? 'Featured' : p.status}
 </div>
                  }
 <div style={{ fontWeight: 700, fontSize: 15, color: '#0D1B2A', marginBottom: 6, lineHeight: 1.4 }}>{p.authors}</div>
 <div style={{ fontSize: 15.5, fontStyle: 'italic', color: '#0D1B2A', marginBottom: 6, lineHeight: 1.45 }}>{p.title}</div>
 {p.source && <div style={{ fontSize: 14, color: '#6B6659' }}>{p.source}</div>}
 {p.note && <div style={{ fontSize: 12.5, color: '#6B6659', marginTop: 8, fontStyle: 'italic' }}>{p.note}</div>}
 {p.link &&
                  <div style={{ marginTop: 12 }}>
 <a href={p.link} target="_blank" rel="noopener" className="link" style={{ fontSize: 13 }}>
 View publication <i data-lucide="external-link" style={{ width: 13, height: 13, marginLeft: 4, verticalAlign: '-2px' }} />
 </a>
 </div>
                  }
 </div>
                )}
 </div>
 </div>);

        })}
 </ProseSection>

 <ProseSection eyebrow="Conferences" title="Conference presentations.">
 <p>SCN2A Australia has presented at the following conferences and events.</p>
 <h4>International</h4>
 <ul>
 <li><strong>HTAi</strong>, Health Technology Assessment International (rare disease and consumer involvement in HTA)</li>
 <li><strong>Global Genes Summit</strong>, Rare disease advocacy leadership</li>
 <li><strong>IRDiRC</strong>, International Rare Diseases Research Consortium (regulatory convergence task force)</li>
 <li><strong>ARCS 2026</strong>, Abstract accepted</li>
 </ul>
 <h4>Australian</h4>
 <ul>
 <li><strong>CHA Leading Thinkers Series</strong>, Children's Healthcare Australasia</li>
 <li><strong>Inaugural Paediatric Palliative Care Conference</strong></li>
 <li><strong>GETA Conference</strong>, Genetic Epilepsy Team Australia</li>
 </ul>
 </ProseSection>

 <ProseSection eyebrow="Podcast & education" title="SCN2A Insights and the webinar programme." background="#F7F4F0">
 <p>The <strong>SCN2A Insights</strong> podcast features conversations with international experts, researchers, and families, translating complex science into accessible knowledge for the SCN2A and DEE community.</p>
 <p>SCN2A Australia also delivers a regular <strong>webinar programme</strong> covering:</p>
 <ul>
 <li>SCN2A genetics, gain vs loss of function explained</li>
 <li>The gene therapy landscape for SCN2A and DEE</li>
 <li>SCN2A and DEE management, and family-centred care</li>
 <li>Consumer engagement in health research</li>
 </ul>
 <p>The <strong>Consumer Engagement in Health Research module</strong> was developed for the University of Melbourne.</p>
 </ProseSection>

 <ProseSection eyebrow="Information resources" title="Downloadable information sheets.">
 <p>Available covering SCN2A genetics and variant types, gene therapy, genetic testing, and DEE explainers, in multiple languages (English, Korean, Chinese, Hindi, Japanese).</p>
 <div style={{ marginTop: 16 }}>
 <Button onClick={() => navigate('resources')}>Browse all resources</Button>
 </div>
 </ProseSection>

 <CTABlock
        eyebrow="Collaborate with us"
        title="If you are a researcher, clinician, or institution interested in partnership, talk to us."
        body="We welcome research collaboration, particularly where the community's lived experience can strengthen study design, recruitment, or knowledge translation."
        ctaLabel="Contact us"
        onCta={() => navigate('contact')} />
      

 <RelatedPages
        items={[
        { label: 'Our Impact', to: 'impact' },
        { label: 'Global Collaboration', to: 'global' },
        { label: 'Partners', to: 'partners' },
        { label: 'Clinical trials', to: 'trials' }]
        }
        navigate={navigate} />
      
 </div>);

}

// -------- Global Collaboration --------------------------------------------

function GlobalCollaborationPage({ navigate }) {
  const networks = [
  { name: 'IBE, International Bureau for Epilepsy', role: 'Community Council member; co-convening SCN2A Global Leaders 2026', url: 'https://www.ibe-epilepsy.org' },
  { name: 'ILAE, International League Against Epilepsy', role: 'Care Pathways Task Force', url: 'https://www.ilae.org' },
  { name: 'Global Genes', role: 'Corporate Council · previous Chair of Global Leaders Council', url: 'https://www.globalgenes.org' },
  { name: 'Rare Diseases International (RDI)', role: 'Affiliated member, UN, WHO, international health policy', url: 'https://www.rarediseasesinternational.org' },
  { name: 'Rare Epilepsy Network (REN)', role: 'Former Coordinating Committee · International Workgroup Lead · ongoing member', url: '' },
  { name: 'Complex and Rare Epilepsies (CREA)', role: 'Participating member', url: '' },
  { name: 'IRDiRC', role: 'Task Force on Regulatory Convergence', url: 'https://www.irdirc.org' },
  { name: 'HTAi', role: 'Committee member, rare disease & patient involvement', url: 'https://www.htai.org' },
  { name: 'E+ Epilepsy Plus Alliance', role: 'Member, rare and complex epilepsies', url: '' },
  { name: 'Epilepsy Foundation Global Research Alliance', role: 'Board of Management (2023–2025)', url: '' },
  { name: 'ISPEP', role: 'Member, International Society for Patient Engagement Professionals', url: '' },
  { name: 'N-1 Collaboration', role: 'Member, individualised and ultra-rare treatments network', url: '' }];

  return (
    <div data-screen-label="Global Collaboration">
 <PageHero
        eyebrow="Research & advocacy"
        title="Global collaboration."
        body="SCN2A is rare. The expertise, the research, the clinical experience, and the families who understand it are spread across the world. Global collaboration is not aspirational for SCN2A Australia, it is essential."
        image={PHOTO.international}
        ledger={["12 INTERNATIONAL ROLES · SINCE 2020", "FOUNDED SCN2A GLOBAL LEADERS NETWORK", "IBE CONVENING · 2026"]}
        navigate={navigate} />
      
 <Breadcrumbs items={[{ label: 'Driving Change', to: 'change' }, { label: 'Global collaboration' }]} navigate={navigate} />

 <ProseSection eyebrow="SCN2A Global Leaders Network" title="A network we founded and convene.">
 <p>In 2020, SCN2A Australia founded and launched the <strong>SCN2A Global Leaders Network</strong>, convening SCN2A patient advocacy organisations and community leaders from around the world to coordinate on research priorities, family support, global awareness, and collaborative initiatives.</p>
 <p>What began as a convening has grown into an active peer network. The SCN2A Global Leaders Network now:</p>
 <ul>
 <li>Coordinates <strong>SCN2A Global Awareness Days</strong>, unified international campaigns raising visibility for SCN2A-related conditions across social media and community channels worldwide</li>
 <li>Drives <strong>collaborative projects</strong> across member organisations, sharing resources, research updates, and advocacy strategies across jurisdictions</li>
 <li>Creates a direct channel between Australian SCN2A families and the global community of families, researchers, and advocates working on the same condition</li>
 </ul>
 </ProseSection>

 <section style={{ background: '#F7F4F0', padding: '72px 0' }}>
 <div className="container">
 <div style={{ marginBottom: 36, maxWidth: 760 }}>
 <div className="eyebrow">International roles</div>
 <h2 className="h2-mobile" style={{ fontSize: 'clamp(28px, 3.4vw, 40px)', fontWeight: 700, color: '#0D1B2A', margin: '14px 0 0', lineHeight: 1.15 }}>Memberships and formal positions across epilepsy, rare disease, HTA, and regulatory science.</h2>
 </div>
 <div style={{ background: '#fff', border: '1px solid #D5CFBF' }}>
 <div style={{ display: 'grid', gridTemplateColumns: '1fr 1.4fr', padding: '14px 24px', background: '#1E3A6E', color: '#fff', fontSize: 12, fontWeight: 700, letterSpacing: '0.06em', textTransform: 'uppercase' }}>
 <span>Organisation</span>
 <span>Role / Engagement</span>
 </div>
 {networks.map((n, i) =>
            <div key={n.name} style={{ display: 'grid', gridTemplateColumns: '1fr 1.4fr', padding: '16px 24px', borderTop: '1px solid #D5CFBF', alignItems: 'center', gap: 16 }} className="stack-mobile-2">
 <span style={{ fontWeight: 700, fontSize: 15 }}>
 {n.url ? <a href={n.url} target="_blank" rel="noopener" className="link">{n.name}</a> : n.name}
 </span>
 <span style={{ fontSize: 14, color: '#6B6659' }}>{n.role}</span>
 </div>
            )}
 </div>
 </div>
 </section>

 <ProseSection eyebrow="Why it matters" title="Why global collaboration matters for Australian families.">
 <p>For a condition as rare as SCN2A, no single country has all the answers, or enough families to run a clinical trial alone. SCN2A Australia's international roles serve a direct purpose for Australian families.</p>
 <div style={{ display: 'grid', gridTemplateColumns: '1fr 1fr', gap: 16, margin: '24px 0' }} className="stack-mobile">
 {[
          ['Access to global research', 'Our network connections mean Australian families are aware of, and connected to, relevant clinical trials, natural-history studies, and research opportunities as they arise, not months after international families have already enrolled.'],
          ['Influence over the therapeutic pipeline', 'Treatments like elsunersen and relutrigine were developed with input from international patient communities. Our presence in global networks ensures Australian families have a voice in shaping how therapies are developed, tested, and evaluated for regulatory approval.'],
          ['Policy that reaches Australia faster', 'Our roles in IRDiRC\'s regulatory convergence work and HTAi are specifically about closing the gap between international drug approval and Australian access, ensuring HTA processes and regulatory frameworks are fit for rare-disease realities.'],
          ['Peer support that transcends geography', 'The SCN2A Global Leaders Network and our connections through IBE and Global Genes mean Australian families can be connected to peers, researchers, and clinicians anywhere in the world, because the right expert or the right family may not be in Australia.']].
          map(([t, b]) =>
          <article key={t} style={{ background: '#fff', border: '1px solid #D5CFBF', padding: '22px 24px' }}>
 <div style={{ fontWeight: 700, fontSize: 17, color: '#0D1B2A', marginBottom: 8 }}>{t}</div>
 <div style={{ fontSize: 14.5, color: '#6B6659', lineHeight: 1.6 }}>{b}</div>
 </article>
          )}
 </div>
 </ProseSection>

 <PullQuote attribution="From our convening work.">
 SCN2A is too rare for any one country to solve alone. <em>Our role is to make sure Australian families are at the table</em>, not waiting for the results.
 </PullQuote>

 <ProseSection eyebrow="2026" title="SCN2A Global Leaders Convening.">
 <p>In 2026, SCN2A Australia is working with IBE to convene SCN2A global leaders formally for the first time, bringing together patient advocacy organisations, researchers, and clinicians from across the SCN2A world.</p>
 <p>This represents a significant step toward a permanent international SCN2A leadership structure with the capacity to coordinate research priorities, share resources, and amplify advocacy globally.</p>
 </ProseSection>

 <CTABlock
        eyebrow="Connect with us"
        title="International organisation, researcher, or family advocacy group?"
        body="If you would like to partner with SCN2A Australia or connect to the SCN2A Global Leaders Network, we’d like to hear from you."
        ctaLabel="Contact us"
        onCta={() => navigate('contact')} />
      

 <RelatedPages
        items={[
        { label: 'Our Impact', to: 'impact' },
        { label: 'Partners', to: 'partners' },
        { label: 'Clinical trials', to: 'trials' },
        { label: 'Publications & presentations', to: 'publications' }]
        }
        navigate={navigate} />
      
 </div>);

}

// -------- Research Opportunities ------------------------------------------

function ResearchOpportunitiesPage({ navigate }) {
  return (
    <div data-screen-label="Research Opportunities">
 <PageHero
        eyebrow="Research"
        title="Research opportunities."
        body="Clinical trials are only one way families shape research. Through the SCN2A Insights Registry, natural-history studies, and family advisory work, every family can contribute to the evidence that drives better diagnosis, treatment, and care, whether or not a trial is right for your child."
        ledger={["REGISTRY · NATURAL-HISTORY · ADVISORY", "OPEN TO ALL SCN2A FAMILIES", "DISCUSS STUDY ELIGIBILITY WITH YOUR TEAM"]}
        navigate={navigate} />
      
 <Breadcrumbs items={[{ label: 'Driving Change', to: 'change' }, { label: 'Research opportunities' }]} navigate={navigate} />

 <section style={{ background: '#fff', padding: '64px 0 0' }}>
 <div className="container">
 <Prose>
 <p style={{ fontSize: 19 }}>
 Research into SCN2A moves at the speed of the data families contribute. Below are the ways you can take part, from a few minutes adding your family to the registry, through to ongoing advisory roles shaping what gets studied and how.
 </p>
 </Prose>
 </div>
 </section>

 <ProseSection eyebrow="Currently recruiting" title="A study on a health questionnaire for children with disability.">
 <p>Researchers at the University of Melbourne are running a qualitative interview study with children and young people living with life-limiting conditions or disability, alongside the parents, caregivers, and clinicians who care for them.</p>
 <p>The study explores a <strong>general health questionnaire</strong> that may be used in research or clinical settings. It asks children (or their parents) to report on everyday difficulties across five areas: mobility; looking after myself; doing usual activities; pain or discomfort; and feeling worried, sad, or unhappy. The team wants to understand how the questionnaire might be improved to better meet the needs of children and young people living with these conditions.</p>
 <SafetyCallout label="What taking part involves">
 Interviews run for 45 minutes to 1 hour, and you will be reimbursed for your time. To express interest, complete a short survey at the link below. Only a small number of participants will be selected, chosen to reflect a range of different experiences, so not everyone who completes the survey will be contacted.
 </SafetyCallout>
 <div style={{ marginTop: 18 }}>
 <Button as="a" href="https://q.surveys.unimelb.edu.au/jfe/form/SV_0Gr5EmHiVgkkJ8i" target="_blank" rel="noopener">Express interest in this study <i data-lucide="arrow-right" style={{ width: 14, height: 14, marginLeft: 4, verticalAlign: '-2px' }} /></Button>
 </div>
 </ProseSection>

 <ProseSection eyebrow="Contribute your data" title="The SCN2A Insights Registry." background="#F7F4F0">
 <p>The <strong>SCN2A Insights Registry</strong> collects de-identified information from families with SCN2A variants to build a picture of the condition, how it presents, how it progresses, and what helps. This data directly informs research directions and clinical-trial design.</p>
 <p>Joining does not commit you to anything else. Your information is used for research purposes only, and by taking part you become part of a global community contributing to a future where better treatments are possible.</p>
 <div style={{ marginTop: 18 }}>
 <Button as="a" href={REGISTRY_SIGNUP_URL} target="_blank">Join the registry <i data-lucide="arrow-right" style={{ width: 14, height: 14, marginLeft: 4, verticalAlign: '-2px' }} /></Button>
 </div>
 </ProseSection>

 <ProseSection eyebrow="Observe & measure" title="Natural-history studies.">
 <p>Natural-history studies follow how SCN2A-related conditions change over time. They are foundational, regulators and trial sponsors rely on them to understand what a meaningful treatment effect looks like, and to design trials with endpoints that matter to families.</p>
 <p>SCN2A Australia helped co-design an Australian DEE natural-history study with a <strong>family-prioritised endpoint set</strong>, in field across multiple sites with Luminesce Alliance. Families who join the registry can be told when studies like this are recruiting.</p>
 <SafetyCallout label="How participation usually works">
 Most natural-history studies involve sharing medical history and completing periodic questionnaires or assessments, with little or no change to your child's care. Your treating team and the study coordinators can explain what is involved before you decide.
 </SafetyCallout>
 </ProseSection>

 <ProseSection eyebrow="Find a study" title="Where to look for recruiting studies." background="#F7F4F0">
 <p><strong>Talk to your neurologist first.</strong> Eligibility for any study depends on your child's variant type, age, and history, your treating team can help you assess whether a study is appropriate.</p>
 <ResourceList title="Useful study-finding resources" items={[
        { label: 'ClinicalTrials.gov', body: 'Search "SCN2A" or "DEE" for all registered trials and observational studies', url: 'https://clinicaltrials.gov' },
        { label: 'Australian New Zealand Clinical Trials Registry', body: 'ANZCTR lists trials and studies recruiting in Australia', url: 'https://www.anzctr.org.au' },
        { label: 'Simons Searchlight', body: 'International natural-history research for SCN2A and related genetic conditions', url: 'https://www.simonssearchlight.org' }]
        } />
 <div style={{ marginTop: 18, display: 'flex', gap: 12, flexWrap: 'wrap' }}>
 <Button onClick={() => navigate('trials')}>See current clinical trials</Button>
 </div>
 </ProseSection>

 <ProseSection eyebrow="Shape the questions" title="Family advisory & co-design.">
 <p>Some of the most valuable research contributions are not clinical at all. Families bring expertise that researchers cannot get anywhere else, what outcomes actually matter, what daily life involves, and what would make a study workable for families.</p>
 <p>SCN2A Australia connects families to advisory and co-design opportunities, including priority-setting work, family advisory panels, and consumer review of study designs. These roles help ensure research is asking the right questions in the first place.</p>
 <div style={{ marginTop: 18, display: 'flex', gap: 12, flexWrap: 'wrap' }}>
 <Button variant="outline" onClick={() => navigate('contact')}>Express interest in advisory work</Button>
 </div>
 </ProseSection>

 <PullQuote attribution="Why participation matters.">
 SCN2A is rare. <em>Every family who contributes makes the evidence base stronger</em> for the families who come after, and brings approved treatments closer.
 </PullQuote>

 <CTABlock
        eyebrow="Get involved in research"
        title="Not sure where to start? We can help you find the right opportunity."
        body="Whether you want to join the registry, find a recruiting study, or contribute to advisory work, a team member can talk you through what is open and what is involved."
        ctaLabel="Talk to us about research"
        onCta={() => navigate('contact')} />
      

 <RelatedPages
        items={[
        { label: 'Clinical trials', to: 'trials' },
        { label: 'Publications & presentations', to: 'publications' },
        { label: 'Our impact', to: 'impact' },
        { label: 'Global collaboration', to: 'global' }]
        }
        navigate={navigate} />
      
 </div>);

}

Object.assign(window, { ClinicalTrialsPage, PublicationsPage, GlobalCollaborationPage, ResearchOpportunitiesPage });